Voyager Therapeutics (NASDAQ:VYGR) Stock Price Down 3.7%

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s share price was down 3.7% during mid-day trading on Thursday . The company traded as low as $7.26 and last traded at $7.29. Approximately 90,007 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 898,971 shares. The stock had previously closed at $7.57.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on VYGR shares. Wells Fargo & Company raised shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $9.00 to $14.00 in a report on Tuesday, January 2nd. Citigroup started coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price target on the stock. HC Wainwright started coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target on the stock. Guggenheim initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Voyager Therapeutics Price Performance

The business’s 50 day moving average is $8.81 and its two-hundred day moving average is $7.96. The firm has a market capitalization of $402.91 million, a PE ratio of 2.40 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The business had revenue of $90.06 million for the quarter, compared to analysts’ expectations of $4.95 million. Analysts expect that Voyager Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Gladius Capital Management LP bought a new position in Voyager Therapeutics during the third quarter valued at approximately $25,000. AJOVista LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter worth approximately $39,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Voyager Therapeutics in the fourth quarter worth approximately $43,000. Tower Research Capital LLC TRC grew its holdings in shares of Voyager Therapeutics by 302.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,399 shares of the company’s stock worth $54,000 after purchasing an additional 4,809 shares during the last quarter. Finally, Aigen Investment Management LP bought a new position in shares of Voyager Therapeutics in the third quarter worth approximately $109,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.